Biomedical Technologies Lead the Future
A wide range of issues of biotechnology and medicine of new technological patterns in Russia were discussed At BIOTECHMED conference held this week in Gelendzhik. This respectable scientific forum met under support of the Ministry of Industry and Trade of the RF and the Ministry of Healthcare of the RF. State Corporation Rostech was a strategic partner.
A strategic dialogue of researchers and practicing professionals was held. The participants discussed information technologies in medicine, prospects of development of the pharmaceutical industry, including production and science.
At the plenary session on state to business cooperation Veronika Skvortsova, Russian Minister of Healthcare, stressed the importance of development of biomedical technologies, including the technologies involved in import substitution policy. She stressed, that recently, Russia’s dependence on international market in the sphere of pharmacology has reduced. New biosimilars have been developed, including target molecular drugs, as new personified medicine solutions, and genetically engineered drugs, not mentioning a large number of bioanalogs and monoclonal antibodies. Talking about prospects, Veronika Skvortsova called attention to Federal Law No 180 On Biomedical Cell Products, approved in June 2016 and coming into effect on January 1, 2017. The Minister remarked, that about 26 biomedical cell-based products meeting the highest standards and showing good effects at the experimental stage, have been developed in Russia. Skvortsova also reported that a law to encourage development of biobank system for adequate storage of biological materials is being developed.
The potential of new Russian developments in the pharmaceutical and medical industry has been highly appreciated by the Minister of Industry and Trade of the Russian Federation Denis Manturov. He remarked, that the biomedical technology sector, accumulating huge potential for breakthrough growth of Russian pharma industry, is the key element of switch of healthcare industry to an innovative model planned in 2020.
The Head of the Ministry of Industry and Trade also reported, that today over 40 local drugs are approved in the Russian market, including 18 drugs authorized within the last 5 years, from 2011 to 2016. The RF Government is planning to bring the number to 150 by 2020. The matter concerns the drugs, that passed so-called “green corridor”, formed by the Ministry of Industry and Trade in cooperation with the Russian Ministry of Health to facilitate the procedure of marketing authorization of new drugs for local manufacturers
Denis Manturov also spoke about public support mechanisms, including compensation of public expenses for launching drugs in the Russian and international markets. He also spoke on the measures developed by the Russian Ministry of Industry and Trade to reimburse the costs for preclinical and clinical trials. The Minister particularly stressed, that to provide pharmaceutical safety within Russia production of locally manufactured drugs at needed volume and supplementation of innovative solutions should be made. Therefore, biotechnologies are a formula for success of the whole pharma industry.